Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer : a TTD and GECOP-SEOQ expert consensus statement
© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO)..
Peritoneal metastases (PM) occur when cancer cells spread inside the abdominal cavity and entail an advanced stage of colorectal cancer (CRC). Prognosis, which is poor, correlates highly with tumour burden, as measured by the peritoneal cancer index (PCI). Cytoreductive surgery (CRS) in specialized centres should be offered especially to patients with a low to moderate PCI when complete resection is expected. The presence of resectable metastatic disease in other organs is not a contraindication in well-selected patients. Although several retrospective and small prospective studies have suggested a survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to CRS, the recently published phase III studies PRODIGE-7 in CRC patients with PM, and COLOPEC and PROPHYLOCHIP in resected CRC with high-risk of PM, failed to show any survival advantage of this strategy using oxaliplatin in a 30-min perfusion. Final results from ongoing randomized phase III trials testing CRS plus HIPEC based on mitomycin C (MMC) are awaited with interest. In this article, a group of experts selected by the Spanish Group for the Treatment of Digestive Tumours (TTD) and the Spanish Group of Peritoneal Oncologic Surgery (GECOP), which is part of the Spanish Society of Surgical Oncology (SEOQ), reviewed the role of HIPEC plus CRS in CRC patients with PM. As a result, a series of recommendations to optimize the management of these patients is proposed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 25(2023), 12 vom: 01. Dez., Seite 3378-3394 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grávalos, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytoreductive surgery |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 09.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12094-023-03204-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356440125 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356440125 | ||
| 003 | DE-627 | ||
| 005 | 20240310231841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-023-03204-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1322.xml |
| 035 | |a (DE-627)NLM356440125 | ||
| 035 | |a (NLM)37140736 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grávalos, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer |b a TTD and GECOP-SEOQ expert consensus statement |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). | ||
| 520 | |a Peritoneal metastases (PM) occur when cancer cells spread inside the abdominal cavity and entail an advanced stage of colorectal cancer (CRC). Prognosis, which is poor, correlates highly with tumour burden, as measured by the peritoneal cancer index (PCI). Cytoreductive surgery (CRS) in specialized centres should be offered especially to patients with a low to moderate PCI when complete resection is expected. The presence of resectable metastatic disease in other organs is not a contraindication in well-selected patients. Although several retrospective and small prospective studies have suggested a survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to CRS, the recently published phase III studies PRODIGE-7 in CRC patients with PM, and COLOPEC and PROPHYLOCHIP in resected CRC with high-risk of PM, failed to show any survival advantage of this strategy using oxaliplatin in a 30-min perfusion. Final results from ongoing randomized phase III trials testing CRS plus HIPEC based on mitomycin C (MMC) are awaited with interest. In this article, a group of experts selected by the Spanish Group for the Treatment of Digestive Tumours (TTD) and the Spanish Group of Peritoneal Oncologic Surgery (GECOP), which is part of the Spanish Society of Surgical Oncology (SEOQ), reviewed the role of HIPEC plus CRS in CRC patients with PM. As a result, a series of recommendations to optimize the management of these patients is proposed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytoreductive surgery | |
| 650 | 4 | |a HIPEC | |
| 650 | 4 | |a Hyperthermia | |
| 650 | 4 | |a Peritoneal carcinomatosis | |
| 650 | 4 | |a Peritoneal metastases | |
| 700 | 1 | |a Pereira, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Arjona-Sánchez, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Losa, Ferran |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a García-Alfonso, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Bayón, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Cascales-Campos, Pedro Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Aranda, Enrique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g 25(2023), 12 vom: 01. Dez., Seite 3378-3394 |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:3378-3394 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-023-03204-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 12 |b 01 |c 12 |h 3378-3394 | ||